Back to search results

Nicotinamide Riboside for Muscle Function in Older Veterans

This study is looking at how Nicotinamide Riboside, a form of vitamin B3, might help improve muscle function and physical abilities in older veterans. As we age, levels of a critical molecule called NAD+ (nicotinamide adenine dinucleotide) can decline, which is linked to weaker muscles and frailty. Nicotinamide Riboside is known to increase NAD+ levels. Researchers want to see if taking Nicotinamide Riboside, compared to a placebo (a pill with no active medicine), can improve things like how much oxygen your body uses during exercise (VO2max), muscle strength, and how fast you walk. They are looking for 74 veterans between 65 and 85 years old to participate.

Study design
This is a double-blind randomized control trial, meaning neither you nor the researchers will know if you are receiving Nicotinamide Riboside or a placebo. The study plans to enroll 74 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes are measured at 12 weeks, suggesting the main study period is at least this long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04691986

Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans

Active, Not Recruiting
NAAges 65–85InterventionalSupportive care
VA Office of Research and Development
~74 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:Nicotinamide RibosidePlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sub-maximal oxygen uptake test (VO2max)
Measured over Change from baseline to endpoint at 12 weeks
+2 more outcomes measured

Conditions

Sarcopenia
Nicotinamide Adenine Dinucleotide Concentration
Muscle Quality and NAD+ Content

Explore related trials

FrailtySarcopenia

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Kenneth L Seldeen, PhD · PRINCIPAL_INVESTIGATOR · Kansas City VA Medical Center, Kansas City, MO

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ages 65-85
Male or female
Any race
Ability to use an exercise bike
Medically cleared for muscle biopsy

Exclusion

Severe Co-morbidity
examples include, but not limited to:
congestive heart failure class equal to or above III
chronic obstructive pulmonary disorder (COPD) gold stage IV
chronic kidney disease equal to or above stage
A VA-SLUMS cognitive screen score of less than or equal to 20
Body mass index greater than or equal to 40

What this trial measures

  • Sub-maximal oxygen uptake test (VO2max)Change from baseline to endpoint at 12 weeks

    Participants are asked to exercise on an recumbent exercise bike as the resistance increases over time. During the exercise, participants are asked to breath through a mask that is connected to a oxygen and carbon dioxide measuring device. Participant will be asked to continue until they report exhaustion, reach 85% of heart rate maximum, or if there are medical concerns. The assessment last for approximately 15 minutes and provides data the pertain to an individuals lung capacity, breathing rate, and endurance.

  • Muscle strengthChange from baseline to endpoint at 12 weeks

    Leg and arm strength will be measured using a small handheld dynamometer where the device is placed on the wrist or ankle as the participant is asked to extend or contract the limb with full force.

  • Gait speedChange from baseline to endpoint at 12 weeks

    Participants are asked to perform a timed walk of approximately 15 feet in length